Your Article Summary
See Latest ArticlesEuropean Commission Approval of New Indication for Roche's Pegasys (peginterferon alfa-2a) Offers Hepatitis C Patients a Second Chance for a Cure
Corporate News Releases - The Healthcare Sales & Marketing Network, 12/05/08
Roche announced that the European Commission has approved Pegasys (peginterferon alfa-2a (0 KD)) plus Copegus (ribavirin) for the retreatment of hepatitis C patients who were not successfully treated with an initial course of interferon alpha (pegylated or non-pegylated), either alone or in combination with ribavirin.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Zoster vaccination: A new opportunity for adult immunization
Canadian Journal of Infectious Diseases, 12/15/09
FDA Approves Newly Revised Prescribing Information For Azilect Reducing Medication And Food Restrictions
Teva Pharmaceutical Industries, 12/15/09
Mylan Receives Approval for Generic Version of Antiepileptic Keppra 1000 mg
Mylan, 12/15/09